Use of Vasa swaras bhavit vardhaman Pippali in patients of Tamak Shwas

A clinical study of Tamak Shwas W.S.R to Bronchial Asthma, with trail drug Vasa Swaras Bhavit Vardhman Pippali a single group clinical trial - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086850

Enrollment

Registered

2025-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J453- Mild persistent asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Both male & female Patients having age greater than or equal to 18years and less than or equal to 60 years of age Patient with chronicity of Tamaka Shwasa Less than 5 years. Patients with classical signs and symptoms of Tamaka Shwasa described in ancient Ayurveda text will be selected for present study such as ShwasaKrichchhata (Dyspnoea) Ghurghurukama (Wheezing sound) Kasa (Cough) Asamyakanidra (Disturbedsleep) Kantodhwamsa (Hoarseness of voice) Pinasa (Coryza) ShleshmaVimokshanteMuhurtam Sukham (After expectoration patient feels better). ParshvaAvgrihyate (Chest tightness) Aasinolabhatesaukhyama (Comfortable in sitting position) Meghambusheetpragvataihi abhivardhate(increase symptoms after weather change) 4.PEF greater than or equal to 50 %

Exclusion criteria

Exclusion criteria: Acute Dyspnoea, Relative Hypoxia And Cyanosis (Status Asthmaticus). Patients suffering from any systemic or chronic illness like Emphysema, Type 2diabetes mellitus, Hypertension, Renal diseases and Cardiac diseases. Patients of Cor pulmonale, Pulmonary Hypertension, Cardiac Asthma and with severe exacerbation. Any acute systemic disease or Infection, post long covid lung disease/complication. Pregnant and lactating mothers. Any malignancy. Acute & serious conditions require immediate intervention will be excluded. PEF less than 50% ILD (Interstitial Lung Disease) Pulmonary Fibrosis and Consolidation Chronicity More Than 5 Year

Design outcomes

Primary

Measure	Time frame
Results will be assessed on the basis of gradation of clinical features of Tamaka ShwasaTimepoint: 7 days 14 days 21 days 30 days 40 days	—

Secondary

Measure	Time frame
Peak flow meter reading to access improvement of lung functionsTimepoint: 2 weeks of completion of clinical trial or treatment	—

Countries

India

Contacts

Public ContactDr Surendra A Soni

Government Akhandanand Ayurved College and Hospital

surendraasoni@gmail.com9408441150

Outcome results